Table 3.
Association of DHEAS in the lowest quartile with pulmonary function and survival in the validation cohort (men and women with fibrotic ILD)
| DHEAS Lowest quartile |
Unadjusted | Adjusted for | ||||
|---|---|---|---|---|---|---|
| Age and sex | Age, sex, IPF and prednisone treatment | |||||
| OR (95% CI) | p-value | OR (95% CI) | p-value | OR (95% CI) | p-value | |
| FVC, % | 0.97 (0.95–0.99) | < 0.001 | 0.96 (0.94–0.98) | < 0.001 | 0.97 (0.95–0.99) | 0.004 |
| DLCO, % | 0.97 (0.95–0.99) | 0.008 | 0.97 (0.95–0.99) | 0.004 | 0.97 (0.95–0.99) | 0.02 |
| CPI | 1.03 (1.00–1.05) | 0.03 | 1.03 (1.01–1.06) | 0.01 | 1.03 (1.00–1.06) | 0.08 |
| HR (95% CI) | p-value | HR (95% CI) | p-value | HR (95% CI) | p-value | |
|---|---|---|---|---|---|---|
| Survivala | 1.96 (0.93–4.11) | 0.07 | 2.30 (1.06–5.00) | 0.03 | 3.17 (1.35–7.44) | 0.008 |
E.g. every one % increase in FVC, %-predicted is associated with a 3% lower odds of a serum DHEAS value in the lowest quartile
CI confidence interval, CPI composite physiologic index, DHEAS dehydroepiandrosterone sulfate, DLCO diffusing capacity of the lung for carbon monoxide, FVC forced vital capacity, HR hazard ratio, ILD interstitial lung disease, OR odds ratio
aTime to death or lung transplantation e.g. patients with DHEAS in the lowest quartile have a 1.96 higher hazard for early death or lung transplant compared to those with normal/high DHEAS